![Kensaku Akita](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Kensaku Akita has worked as a Director at Applizyme, Inc. and as a Manager at Yoshindo, Inc.
Kensaku Akita active positions
Companies | Position | Start |
---|---|---|
Applizyme, Inc.
![]() Applizyme, Inc. BiotechnologyHealth Technology Applizyme, Inc. is a holding company that develops deoxygenize activity for polychlorinated biphenyls (PCBs). It develops and offers technologies designed to render harmful substances harmless by using microorganisms and enzymes derived from those microorganisms. The firm’s solutions and technologies detoxify persistent organochlorine compounds, such as PCBs, and provide joint-storage for microbes that have industrial uses. The company was founded on August 10, 2011 and is headquartered in Yonezawa, Japan. | Director/Board Member | - |
Yoshindo, Inc.
![]() Yoshindo, Inc. Pharmaceuticals: MajorHealth Technology Yoshindo, Inc. is a pharmaceutical company based in Japan that specializes in producing high-quality generic drugs, essential drugs for infusion and dialysis, and conducting research and development of biopharmaceuticals. The Japanese company aims to become an indispensable player in the pharmaceutical industry in Japan. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Yoshindo, Inc.
![]() Yoshindo, Inc. Pharmaceuticals: MajorHealth Technology Yoshindo, Inc. is a pharmaceutical company based in Japan that specializes in producing high-quality generic drugs, essential drugs for infusion and dialysis, and conducting research and development of biopharmaceuticals. The Japanese company aims to become an indispensable player in the pharmaceutical industry in Japan. | Health Technology |
Applizyme, Inc.
![]() Applizyme, Inc. BiotechnologyHealth Technology Applizyme, Inc. is a holding company that develops deoxygenize activity for polychlorinated biphenyls (PCBs). It develops and offers technologies designed to render harmful substances harmless by using microorganisms and enzymes derived from those microorganisms. The firm’s solutions and technologies detoxify persistent organochlorine compounds, such as PCBs, and provide joint-storage for microbes that have industrial uses. The company was founded on August 10, 2011 and is headquartered in Yonezawa, Japan. | Health Technology |
- Stock Market
- Insiders
- Kensaku Akita